Clinical trials: Standard treatment
Hyperkalemia
Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management
When a patient arrives to an emergency department and is found to have an elevated potassium level in the blood, there is no one standardized treatment, therefore it is not known if one treatment is superior to other.
- Trial name
- PLATINUM (NCT04443608)
- Testing
- Patiromer Powder for Oral Suspension [Veltassa]
- Where
- 19 sites in United States
- Volunteers
- 115 people
- Sponsor
- Comprehensive Research Associates
Diabetes Mellitus, Type 2
Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus
Primary Objective: To compare patient-led titration (intervention group) versus physician-led titration (usual standard of care) in optimizing the clinical use of insulin glargine in an Asian population of patients with Type 2…
- Trial name
- ATLAS (NCT01169818)
- Testing
- Insulin Glargine
- Where
- 6 sites in China, India and 4 more
- Volunteers
- 555 people
- Sponsor
- Sanofi
Prostate Cancer
Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer
To compare the safety of efficacy of abarelix versus goserelin plus bicalutamide in patients with advanced or metastatic prostate cancer.
- Trial name
- NCT00841113
- Testing
- Abarelix, Goserelin plus Bicalutamide
- Volunteers
- 177 people
- Sponsor
- Speciality European Pharma Limited
Hemorrhage, Soft Tissue Bleeding
EVARREST™ Fibrin Sealant Patch Post-Market Study
The objective of this study is to evaluate the clinical utility of EVARREST™ Fibrin Sealant Patch (Fibrin Pad) as an adjunct to hemostasis in soft tissue bleeding during intra-abdominal (stomach area), retroperitoneal (hip and…
- Trial name
- EVARREST (NCT01902459)
- Testing
- EVARREST™ Fibrin Sealant Patch, Standard of Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Ethicon, Inc.
Hypertension, Vascular Diseases
SPYRAL GEMINI Pilot Study
The purpose of the SPYRAL GEMINI Pilot Study is to evaluate that multi-organ denervation with the Gemini System is safe and provide evidence of blood pressure reduction when studied in an uncontrolled hypertensive population with…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SPYRAL GEMINI (NCT06907147)
- Testing
- Multi-Organ Denervation Gemini System
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Vascular
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome
The purpose of this study is to determine the activity of tamibarotene in participants with relapsed/refractory (R/R) AML (administered as a monotherapy or in combination with azacitidine), R/R higher-risk MDS (HR-MDS)…
- Trial name
- NCT02807558
- Testing
- Tamibarotene, Azacitidine, Daratumumab
- Where
- 26 sites in United States, France
- Volunteers
- 155 people
- Sponsor
- Syros Pharmaceuticals
Venous Ulcers
Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
This study will test the safety and efficacy of nitric oxide gas in the treatment of venous leg ulcers
- Trial name
- NCT00545298
- Testing
- Nitric Oxide - same dose 6 wks, Nitric Oxide modified treatment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Nitric BioTherapeutics, Inc
Multiple Myeloma
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of…
- Trial name
- iMMagine-3 (NCT06413498)
- Testing
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine
- Where
- 117 sites in United States, Australia and 13 more
- Volunteers
- 452 people
- Sponsor
- Kite, A Gilead Company
Irregular Menstrual Cycle
Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan
Dydrogesterone is approved in more than 100 countries including Russia, Ukraine, Kazakhstan and Uzbekistan and widely used for the treatment of progesterone deficiencies such as for management of dysmenorrhea, endometriosis…
- Trial name
- NCT01711216
- Where
- 66 sites in Kazakhstan, Russia and 2 more
- Volunteers
- 999 people
- Sponsor
- Abbott
Acute Myocardial Infarction
COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction
COOL AMI EU Pilot Trial: A Multicenter, Prospective, Randomized Controlled Trial to Assess Cooling as an adjunctive Therapy to Percutaneous Intervention in Patients with Acute Myocardial Infarction.
- Trial name
- NCT02509832
- Testing
- Cooling + PCI, PCI only
- Where
- 13 sites in Austria, Estonia and 6 more
- Volunteers
- 100 people
- Sponsor
- ZOLL Circulation, Inc., USA
Kidney Transplant
Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients
Many people who receive a kidney transplant develop problems with how their body processes sugar (glucose). This includes conditions like prediabetes and diabetes, which can lead to more health issues, such as heart problems and…
- Trial name
- TARGET (NCT06833463)
- Testing
- LCP Tacro (tacrolimus)
- Where
- 6 sites in Poland
- Volunteers
- 120 people
- Sponsor
- Chiesi Poland Sp. z o.o.
Parkinson's Disease (PD)
A Study to Evaluate the Efficacy and Safety of ENERGI-F705 Tablets for Parkinson's Disease
The goal of this clinical trial is to learn if this study drug, ENERGI-F705 Tablets, is safe and works to treat participants who have Parkinson's disease and are currently on standard-of-care antiparkinsonian medications.
- Trial name
- NCT07647614
- Testing
- 60 milligrams of ENERGI-F705 Tablets, 120 milligrams of ENERGI-F705 Tablets
- Where
- 2 sites in Taiwan
- Volunteers
- 105 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation
Solid Tumors
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Phase 2, open-label study that will evaluate the safety, tolerability, antitumor activities.
- Trial name
- NCT03616834
- Testing
- Tomivosertib (eFT-508)
- Where
- 19 sites in United States
- Volunteers
- 39 people
- Sponsor
- Effector Therapeutics
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone…
- Trial name
- NCT00877006
- Testing
- bendamustine, rituximab, vincristine
- Where
- 128 sites in United States, Australia and 5 more
- Volunteers
- 447 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Prader-Willi Syndrome
Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome
The primary objective of this study is to assess the efficacy of cannabidiol oral solution on hyperphagia-related behavior in patients with Prader-Willi Syndrome (PWS).
- Trial name
- NCT02844933
- Testing
- Cannabidiol
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- Radius Pharmaceuticals, Inc.
Breastfeeding, Education, Nursing
Effect of a Newborn Simulator's Fidelity on Nursing Students' Level of Engagement in a Clinical Lactation Encounter
Nursing students (N=32) will be randomized to begin period 1 in either a high-fidelity or low-fidelity simulated experience with a mock patient wearing a breast model and holding a newborn simulator and then cross over in period…
- Trial name
- NCT05316909
- Testing
- Breastfeeding Simulation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- LiquidGoldConcept
Diabetic Foot Ulcers
A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers
This study has been designed to help determine how safe and effective DermaPure™ may be in treating hard-to-heal diabetic foot ulcers compared to the current standard of care.
- Trial name
- NCT02081352
- Testing
- DermaPure™, Standard care
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- TRx Wound Care Limited
Complicated Urinary Tract Infection, Acute Pyelonephritis
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the…
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- Integral-2 (NCT05905055)
- Testing
- co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT
- Where
- 54 sites in China, Croatia and 12 more
- Volunteers
- 126 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Femoral Artery Stenosis, Popliteal Artery Stenosis
MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery
The purpose of this trial is to assess the safety and efficacy of MDT-2113 for the interventional treatment of de novo and non-stented restenotic lesions in the superficial femoral artery (SFA) and the proximal popliteal artery…
- Conditions
- Femoral Artery Stenosis, Popliteal Artery Stenosis, Femoral Artery Occlusion, Popliteal Artery Occlusion
- Trial name
- MDT-2113 SFA (NCT01947478)
- Testing
- MDT-2113 Drug-Eluting Balloon, Standard angioplasty balloon
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Medtronic Endovascular
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.